Navigation Links
Still River Systems Sign Patent License Agreement With the Massachusetts Institute of Technology
Date:6/22/2011

LITTLETON, Mass., June 22, 2011 /PRNewswire/ -- Still River Systems, Inc. announces today that it has entered into a long-term licensing agreement with the Massachusetts Institute of Technology (M.I.T.) to utilize advanced superconducting accelerator technologies developed at M.I.T.'s Plasma Science and Fusion Center in collaboration with Still River.  Still River will employ those technologies in conjunction with its own leading-edge developments in its groundbreaking single-room proton therapy platform, the Monarch250. This unique medical device houses a revolutionary source of high-energy protons based on the world's highest field strength superconducting synchrocyclotron that provides a significant reduction in the size, cost, and complexity of developing and operating a proton therapy center.

The precision of proton therapy makes it an important treatment option for patients with cancer. Protons can be directed to concentrate their energy precisely on the cancerous tumor while sparing the surrounding healthy tissue, resulting in far fewer short and long-term treatment complications. The first Monarch250 is currently under installation at the Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine in St. Louis, MO, a National Cancer Institute (NCI) Comprehensive Cancer Center.

The proton accelerator has been undergoing complete clinical testing and commissioning, including lifetime testing, and all clinical parameters have exceeded performance expectations. "The innovative design of our proton therapy platform, aided by the technology developed with M.I.T., results in a simple and modular system thus enabling quick, efficient, and cost effective installations," states CEO Joseph Jachinowski. "With our first system nearing completion, we are now beginning to reap the benefits of its unique design by finalizing a complete process that can be replicated to meet the growing proton therapy demand in a cost-efficient manner."

Still River Systems will be exhibiting at the Annual Meeting of the American Association of Physicists in Medicine (AAPM) in Vancouver, British Columbia on July 31st through August 3rd.  

ABOUT STILL RIVER SYSTEMS

Still River Systems, Inc., based in Littleton, Massachusetts, is dedicated to providing physicians, and their patients, access to high quality, cost-effective proton therapy solutions. Still River Systems is developing the Monarch250, an affordable, precise and compact proton therapy system for cancer treatment.

The Monarch250 has not been cleared by the US Food and Drug Administration for distribution or clinical use. For more information on Still River Systems and the Monarch250 Proton Therapy System, please call 978-540-1500 or visit www.stillriversystems.com


'/>"/>
SOURCE Still River Systems
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. National Nasal Allergy Survey Reveals Unmet Needs Still Exist Among Patients Living With Allergic Rhinitis
2. Despite New Changes, Highmark Policy Still Threatens Patients With Primary Immunodeficiency Diseases
3. Report: Inappropriate Antibiotic Use Still High Despite Educational Efforts
4. Video and Stills from Bill & Melinda Gates Foundation Available on thenewsmarket.com: UK Government and Bill & Melinda Gates Foundation Announce New Commitment to Eradicating Polio
5. Reportlinker Adds Pharmaceutical M&A in the Asia-Pacific Region - India and China drive regional activity but Japan still dominates high value transactions
6. Still River Systems Announces Production Milestone for the Worlds Smallest High-Energy Proton Therapy Accelerator
7. Medco Study: Despite FDA Warnings, Nearly One-Third of Asthma Patients Still Treated with Long-Acting Beta Agonists Without Controller Medications, Increasing Their Risk for Complications and Hospitalizations
8. First Perry Baromedical Sigma Elite Hyperbaric Chamber with EMR Installed at Stillwater Medical Center
9. Toxic Chemical bisphenol A Still Not Banned By FDA; Schumer, Gillibrand Call for Ban; Govt Official Warns Public
10. Pennsylvania Department of Health Begins Statewide H1N1 Vaccination Clinics Targeting Priority Populations; Some Appointments Still Available
11. U.S. Department of Defense Awards $1.2 Million to Study the Use of Vigabatrin to Reduce the Addictive Liability of Opiates While Still Effectively Managing Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/5/2017)... ROSEMONT, Ill. , Oct. 5, 2017 /PRNewswire-USNewswire/ ... American Association of Oral and Maxillofacial Surgeons (AAOMS) ... than opioids – to be used as a ... post-surgical pain. ... relationship, the AAOMS White Paper "Opioid Prescribing: Acute ...
(Date:10/2/2017)... Lilly and Company (NYSE: LLY ) will ... 2017 on Tuesday, October 24, 2017. Lilly will also ... investment community and media to further detail the company,s ... at 9 a.m. Eastern time. Investors, media and the ... conference call through a link that will be posted ...
(Date:9/28/2017)... Sept. 28, 2017 Cohen Veterans Bioscience and ... use of wearable and home sensors for real-time monitoring ... Signal Foundation, a nonprofit organization focused on disruptive health ... an affordable analytical system to record and integrate behavioral, ... ...
Breaking Medicine Technology:
(Date:10/13/2017)... SAN LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... with Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for ... mean is the 90-day elimination period, when the family pays for care, is often ...
(Date:10/13/2017)... Abilene, Texas (PRWEB) , ... October 13, 2017 , ... ... publication this week that explains one of the most popular and least understood books ... seems like cryptic and puzzling descriptions that have baffled scholars for centuries. Many have ...
(Date:10/13/2017)... ... ... “America On The Brink”: the Christian history of the United States and the loss ... author, William Nowers. Captain Nowers and his wife, Millie, have six children, ten ... the Navy. Following his career as a naval aviator and carrier pilot, he ...
(Date:10/12/2017)... ... 2017 , ... The company has developed a suite of ... authorities worldwide. From Children’s to Adults 50+, every formula has been developed by ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, Preservative ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... drug delivery system that we intend to develop to enable prevention of a ... lead to severe hearing loss, especially in pediatric patients. For cisplatin, hearing loss ...
Breaking Medicine News(10 mins):